ND0612H: Preliminary Ph IIa Trial 006 data

Preliminary data from the observer-blind, international Phase IIa Trial 006 in 38 advanced PD patients showed that continuous 24-hour treatment with ND0612H met the primary endpoint of reducing daily “off” time vs. baseline (2.7 vs. 5.5 hours, p=0.004). Patients received continuous 24-hour treatment with 720/90 mg ND0612H levodopa/carbidopa at a high day rate for 18 hours and a low night rate

Read the full 614 word article

How to gain access

Continue reading with a
two-week free trial.